C07K 16/244
Interleukins [il]
Official title: {Interleukins [IL]}
C07K16/244 (Interleukins [il]) appears on 2,184 US grants and 4,147 published applications in this corpus.
Search patents in C07K- Granted patents
- 2,184
- Published applications
- 4,147
- Assignees
- 1,066
- Inventors
- 6,136
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 4 | 0 |
| 1995 | 1 | 0 |
| 1996 | 5 | 0 |
| 1997 | 20 | 0 |
| 1998 | 25 | 0 |
| 1999 | 30 | 0 |
| 2000 | 21 | 0 |
| 2001 | 20 | 4 |
| 2002 | 22 | 29 |
| 2003 | 16 | 71 |
| 2004 | 18 | 49 |
| 2005 | 20 | 70 |
| 2006 | 28 | 61 |
| 2007 | 31 | 74 |
| 2008 | 19 | 87 |
| 2009 | 52 | 109 |
| 2010 | 68 | 149 |
| 2011 | 76 | 141 |
| 2012 | 80 | 153 |
| 2013 | 98 | 155 |
| 2014 | 91 | 218 |
| 2015 | 75 | 165 |
| 2016 | 116 | 184 |
| 2017 | 141 | 193 |
| 2018 | 118 | 212 |
| 2019 | 97 | 225 |
| 2020 | 142 | 292 |
| 2021 | 151 | 274 |
| 2022 | 126 | 252 |
| 2023 | 98 | 275 |
| 2024 | 131 | 259 |
| 2025 | 116 | 204 |
| 2026 | 109 | 242 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Antibodies against human TSLP and use thereof6 Oct 2026US 12,753,227 B2Beijing Wisdomab Biotechnology Co., Ltd
- Manufacturing methods for producing anti-IL12/IL23 antibody compositions29 Sep 2026US 12,747,289 B2Janssen Biotech, Inc.
- IL-33 binding antibodies29 Sep 2026US 12,747,290 B2GlaxoSmithKline Intellectual Property Development Limited
- Pharmaceutical products and stable liquid compositions of IL-17 antibodies22 Sep 2026US 12,741,024 B2Novartis AG
- Pharmaceutical composition containing antibody against IL-5 and use thereof22 Sep 2026US 12,742,004 B2Jiangsu Hengrui Medicine Co., Ltd.
- Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy8 Oct 2026US 2026/0306543 A1The McLean Hospital Corporation
- Method of treating crohn's disease with a combination of antibodies to il-23 and tnf alpha8 Oct 2026US 2026/0308243 A1Janssen Biotech, Inc.
- A high-concentration monoclonal antibody formulation and uses thereof8 Oct 2026US 2026/0308245 A1Jiangsu Biojetay Biotechnology Co., Ltd.
- Methods of treating inflammatory diseases8 Oct 2026US 2026/0308246 A1Boehringer Ingelheim International GmbH
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308247 A1Novartis AG
Most cited
By later US patents
- Method of making transgenic mice lacking endogenous heavy chains1,057US 5,939,598 AAbgenix, Inc. · 1999
- Human antibodies derived from immunized xenomice1,057US 6,075,181 AAbgenix, Inc. · 2000
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Human antibodies derived from immunized xenomice943US 6,150,584 AAbgenix, Inc. · 2000
- Generation of xenogeneic antibodies639US 6,114,598 AAbgenix, Inc. · 2000